Diamond BioPharm

Diamond BioPharm, part of the Diamond Pharma Services group, is a leading technical consultancy providing regulatory affairs and product development services to the biopharmaceutical industry. The company specializes in supporting the development of various therapeutic modalities, including advanced therapy medicinal products (ATMPs), biologics, and small molecules. Their expertise spans from early-stage development and CMC strategy to clinical trial applications and marketing authorization submissions. Diamond BioPharm is recognized for its deep understanding of European and global regulatory frameworks, helping clients navigate complex pathways to bring innovative medicines to market. In 2021, the company was acquired by PharmaLex, further expanding its global reach and service capabilities.